The Industrial Technology Research Institute (ITRI), this year, held the 2008 International Symposium on Chronic Hepatitis and Liver Diseases at NTUH International Conference Center from December 6th to 7th. For this symposium, ITRI sincerely invited many international leading experts and authorities to take part in, making discussion about The Current Status of the Treatment for Chronic Hepatitis C Virus Research; the major participants in this conference included Mr. Ya Jin-Chuan, the Deputy Minister of Dept. of Health, Prof. Chen Ding-Sin, the ex-Dean of HTUH, Mr. Liou Jhong-jheng, the Director of ITRI’s Biomedical & Engineering Research Laboratories (BERL), David A. Brenner, the Dean of School of Medicine in San Diego University, U.S., Dr. Augusto Villanueva from Span, and Dr. Masahiro Satake, the Director of Red-Cross Blood Center in Japan. More than hundreds of magnates such as authoritative doctors, leading experts, and industrial owners related in liver diseases participated in it, targeting on the two issues; one is the up-to-date experiences of medicine development & new therapy for hepatitis C; the other, the current status of prevention & treatment and future research direction.
''To combine many domestic fundamental studies on anti-hepatitis, dealing with liver diseases for compatriots in priority,” the Director of ITRI’s BERL, Liou Jhong-Jheng, declared, “ITRI actively promotes the Chinese herbal medicine & botanical new drugs against hepatitis in recent years, and has gained some initial achievement. Now, ITRI hopes integrate both academic results & industrial strength in Taiwan with international research institutes & drug firms related in liver diseases, leading Taiwan to stand in a key position.” In the past few years, ITRI’s BERL has developed the leading medicine—Anti-Hepatitis B Botanic New Drug (BMEC-101) & CATC 701. Furthermore, ITRI set up the filtering platform & the evaluation mode of pharmacological activity for anti-hepatitis C drugs; meanwhile, it also built up the platform & the mode for anti-arthritis drugs, the procedure for drugs, component separator of pharmacological activity, database for botanic drugs, and forum of metabolism. In addition, it set up the SOP for technical documents of IND (Investigatory New Drug), guiding Taiwan to become as a global indispensable role in developing botanic drugs and small molecular medicine.
'Taiwan, dedicated itself in study of hepatitis for a long time,” said Prof. Chen Ding-Sin, the Doctor of HTUH, “at present, it has created a great amount of achievement and owned many outstanding clinical research talents. Now, we wish to increase the opportunities of interaction for international collaboration.” Due to the rich experiences of clinical studies in Taiwan, the conference set up the topics from Diagnosis, Treatment, and Prevention on Hepatitis to the Study of HCV Complication and Liver Transplantation, inviting several international instructors together in this forum, such as Prof. Lai Ming-Chiao, the President of National Cheng Kung University, Dr. Kao Jia-Horng in NTUH, Mr. Chen Jhao-Long, the Dean of Kaohsiung Chang Gung Memorial Hospital, Ming-Chu Hsu, the Chairman & CEO of TaiGen Biotechnology Co., Ltd., Zeng Zih-Lin, the Vice Director of ITRI’s Biomedical and Engineering Research Laboratories, David A. Brenner & Christopher M. Walker from U.S., and Masahiro Satake from Japan.
Taking positive side of anti-hepatitis C drugs for business opportunities in global markets—approximately USD 6 billion a year (about NTD 2 trillion), now, lots of drug firms actively take part in Taiwan’s clinical examination for hepatitis C. To manifest Taiwan’s superiority on study of liver diseases, the organizer held the forum for industries on the second day to provide the chances of interaction and communication for both domestic and international drug firms. In the future, ITRI will combine many researches & techniques among international countries, setting up the platform & mode for collaboration to guide further development for biomedical and engineering industries. It aimed at leading biomedical and engineering industries to promote their own CRO, CMO, internationalized medical care services, investigation on new drugs, medical equipments, and bio-medicament, creating more new business chances as the purpose.
Betty Hsu, ITRI